ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
3.5000
-0.0400 (-1.13%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous close3.5400
Open3.5800
Bid2.71 x 1000
Ask6.00 x 1400
Day's range3.4100 - 3.6200
52-week range2.5100 - 10.4390
Volume16,166
Avg. volume20,170
Market cap141.495M
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.31
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.38
Trade prices are not sourced from all markets
  • The Wall Street Journal4 days ago

    [$$] Aslan Reports Positive Data From Study Combining Its Drug With Chemotherapy

    Ltd. (ASLN) reported positive data Monday from a Phase 1b/2 trial of its varlitinib drug in combination with chemotherapy in first-line biliary tract cancer. The company said the responses in the trial were “impressive,” and that the drug has been well tolerated in biliary tract cancer patients. On Sunday, Aslan said a phase 2 combining varlitinib with mFOLFOX6 in gastric cancer patients didn’t meet its primary endpoint.

  • GlobeNewswire4 days ago

    ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced positive data from an ongoing multicentre phase 1b/2 clinical trial (ASLAN001-007) of varlitinib plus gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC). Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “The responses we have seen with varlitinib in this clinical trial are impressive, especially when compared to historical data for the current standard of care, gem/cis for biliary tract cancer. Apart from combination chemotherapy, no progress has been made in the development of new treatment options for BTC patients.

  • ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
    Zacks5 days ago

    ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

    ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

  • GlobeNewswire5 days ago

    ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update on its global placebo-controlled, double-blind phase 2 clinical study of varlitinib as a first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients, comparing varlitinib plus mFOLFOX6 to placebo plus mFOLFOX6. To date, no targeted therapies have been approved to treat gastric cancer with low HER-family expression.

  • GlobeNewswire15 days ago

    ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug (IND) application for ASLAN003. The company plans to evaluate ASLAN003 in the United States as part of an ongoing Phase 2 clinical trial. ASLAN003 is a potential treatment for acute myeloid leukaemia (AML), for which the FDA has previously granted Orphan Drug Designation.

  • GlobeNewswire17 days ago

    ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of patient enrolment in TreeTopp (TREatmEnT OPPortunity), a global pivotal study investigating varlitinib in second-line biliary tract cancer (BTC). It is the largest global, placebo-controlled study in BTC conducted to date. The study recruited 127 patients who have failed first line therapy from 56 sites worldwide including the US, Europe, Australia, Japan, Korea and other Asia Pacific countries.

  • GlobeNewswire2 months ago

    New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new positive data from the ongoing phase 2a study of ASLAN003 for the treatment of acute myeloid leukaemia (AML) at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, US. ASLAN003 is an orally active, potent inhibitor of dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in AML. As of 16 November 2018, 14 patients with AML ineligible for standard treatment (including relapsed, refractory and treatment naïve) had been enrolled in the multicentre dose optimisation study to evaluate ASLAN003 monotherapy administered as a 28-day cycle.

  • GlobeNewswire2 months ago

    ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium

    SINGAPORE, Nov. 27, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.

  • GlobeNewswire2 months ago

    Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation in the 30th Annual Piper Jaffray Healthcare Conference. A live audio webcast of the fireside chat will be available via https://event.webcasts.com/starthere.jsp?ei=1220246&tp_key=5121f6637a with an archived replay link available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event. ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets.

  • GlobeNewswire2 months ago

    ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    SINGAPORE, Nov. 08, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.

  • GlobeNewswire3 months ago

    ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting

    SINGAPORE, Nov. 01, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.

  • GlobeNewswire3 months ago

    ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced today the appointment of Robert E. Hoffman as an Independent Non-Executive Director. Mr. Hoffman has more than 20 years of experience in leading and managing global biotechnology companies, and working with a number of public, late-stage oncology companies. In planned board changes following ASLAN’s listing on NASDAQ earlier this year, Professor Lai Mei-Shu and Dr. Jerome Shen, who served as Independent Non-Executive Director and Non-Executive Director respectively, will step down from ASLAN’s Board of Directors concurrently.

  • GlobeNewswire3 months ago

    New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours. The study findings, presented in a poster session today at the 2018 European Society for Medical Oncology (ESMO) Congress, indicate encouraging signs of efficacy for varlitinib as a treatment for late-stage oncology patients. The investigator-initiated trial was conducted by Dr Matthew Chau Hsien Ng and supported by ASLAN and the Singapore National Medical Research Council.